missing translation for 'onlineSavingsMsg'
Learn More

R&D Systems™ Recombinant Human CCL3L1/LD78 beta

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity

Brand:  R&D Systems™ 509-MI-025/CF

Product Code. 18186790

  • 249.00 EUR / 25µg

Please to purchase this item. Need a web account? Register with us today!

Explore more special offers
This item is not returnable. View return policy

Description

Description

The Recombinant Human CCL3L1/MIP-1 alpha Isoform LD78 beta is derived from E. coli. The Recombinant Human CCL3L1/MIP-1 alpha Isoform LD78 beta has been validated for the following applications: Bioactivity.
Specifications

Specifications

Lyophilized from a 0.2μm filtered solution in Acetonitrile and TFA.
7.8 kDa
25μg
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution.
Recombinant
6349
CCL3L1/MIP-1 alpha Isoform LD78 beta
E. coli-derived human CCL3L1/MIP-1 alpha Isoform LD78 beta protein Ala24-Ala93
Unconjugated
97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Special Offers

Special Offers

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.